About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 417 record(s)
Req # A-2022-001260
All records regarding the development, publication and promotion of Dr Theresa Tam‘s video with "Mrs. Claus", published online on or about Dec. 21, 2022.Organization: Health Canada
June 2023
Req # A-2022-001388
The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the drug establishment licence Good Pharmacovigilance Practices (GVP) inspection of the CRLS facility (Site A) located at 333 24 Ave SW, 300, Calgary, Alberta starting around 24 January 2022. Reference Number 500172.Organization: Health Canada
June 2023
Req # A-2022-001481
Respirator recalls https://recalls-rappels.canada.ca/en/alert-recall/medical-device-respirator-recalls. Updates in which Health Canada issues a warning against the use of certain types of KN95s in the hospital setting. The various versions of this Notice to see the changes made with each update.Organization: Health Canada
June 2023
Req # A-2022-001533
The latest copy of the organization chart for each division within the Regulatory Operations and Enforcement Branch of Health Canada that employs inspectors.Organization: Health Canada
June 2023
Req # A-2022-001538
Any briefing notes, discussion papers, reports, or presentations done from January 1, 2018 to December 31, 2021 on best practices of the healthcare systems of other countries and how they compare to those in Canada.Organization: Health Canada
June 2023
Req # A-2022-001575
Written policies and procedures of Health Canada Exemptions section for dealing with Exemption Applications under subsection 56(1) exemption as it pertains to religious exemptions.Organization: Health Canada
June 2023
Req # A-2022-001587
All submissions made by Sunshine Labs made to Health Canada for an amendment to include cocaine under a Controlled Substances Dealer’s License. Restrict Search to the Office of Controlled Substances. Date range for Records Search: 09/01/2022 to 12/31/2022.Organization: Health Canada
June 2023
Req # A-2022-001662
All work descriptions for IS-03, IS-04 and IS-05 level positions where the main responsibilities/duties of the position involve the web and/or social media.Organization: Health Canada
June 2023
Req # A-2023-000024
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Levothyroxine sodium. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Levothyroxine sodium which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24. The strength (s) and dosage form of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Levothyroxine sodium.Organization: Health Canada
June 2023
Req # A-2023-000048
The initial cover letter indicating the brand name of the reference drug product and the dosage form of any generic submission (ANDS) having the medicinal ingredient Tolvaptan. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Tolvaptan. The strength (s) and dosage form of any and all generic drugs having the medicinal ingredient Tolvaptan. The Canadian Reference product (strength (s) and dosage form) used to support any generic submission (ANDS) having the medicinal ingredient Tolvaptan.Organization: Health Canada
June 2023